The WATCHMAN FLX device showed superior safety with 8.5% major bleeding at 36 months, compared to 18.1% with oral ...

The trial met its primary safety and efficacy endpoints, demonstrating the device's superiority to oral anticoagulants.

Boston Scientific announced positive three-year primary endpoint results from a clinical trial of its Watchman FLX device.

In a report released on November 15, David Rescott from Robert W. Baird maintained a Buy rating on Boston Scientific (BSX – Research Report), ...

Mizuho Securities analyst Anthony Petrone has maintained their bullish stance on BSX stock, giving a Buy rating yesterday.Don't Miss our Black ...

Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...

Boston Scientific (BSX) stock climbed 5% after a study showed its Watchman FLX device was superior to oral anti-coagulants in reducing bleeding risks following cardiac ablation.

Marlborough, Massachusetts Tuesday, November 19, 2024, 17:00 Hrs [IST] ...

Boston Scientific Corporation BSX recently announced favorable three-year primary endpoint data from the OPTION global ...

Although some of the trial’s methodology was critiqued, the results provide fodder for shared decision-making discussions.

Abbott has reported late-breaking five-year positive data from a trial of its Amplatzer Amulet left atrial appendage (LAA) ...

At the moment, the company is developing novel therapeutic approaches for patients with underserved heart issues, such as ...